ReviewFrontiers in stroke2026
Reframing moyamoya vasculopathy within steno-occlusive disease of the circle of Willis.
Review in Frontiers in stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moyamoya disease (MMD) is classically defined by progressive steno-occlusion of the terminal internal carotid artery (ICA) with associated basal collateral networks. Historically, however, this condition was conceptualized in Japan as part of a broader anatomical category-steno-occlusive disease of the circle of Willis (SOCW)-which preceded disease-specific nomenclature. Increasing genetic, developmental, and clinical evidence now challenges the strict separation between MMD and moyamoya syndrome (MMS). In this narrative review, we re-examine moyamoya-related conditions within a unified, location-defined framework and propose three advances: (1) an operational definition of SOCW with explicit anatomical boundaries; (2) a spectrum-based classification distinguishing phenotype from etiologic context; and (3) a refined, location-based multi-hit model integrating developmental vulnerability, genetic susceptibility, and acquired triggers. Historical analysis indicates that SOCW was originally defined as an anatomical category, within which moyamoya vasculopathy (MMV) represents the predominant but non-exclusive angiographic phenotype. Genetic studies identify RNF213 as a major susceptibility modifier influencing phenotypic expression and population prevalence, although substantial ethnic heterogeneity and incomplete penetrance indicate that RNF213 is neither necessary nor sufficient for disease development. Additional genetic and environmental factors may further influence disease expression. Developmental factors may contribute to the characteristic localization of disease, although current evidence remains indirect. This SOCW-based framework provides a structured approach to intracranial steno-occlusive disorders, facilitates interpretation of early or atypical presentations, and supports multimodal and longitudinal assessment rather than rigid categorical labeling. By integrating anatomical, genetic, and clinical dimensions, this model offers a pragmatic and biologically grounded basis for future research and refinement of disease classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.